Free tool
FAERS Monitor: Sandostatin Lar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021008 or its brand name (Sandostatin Lar, Octreotide Acetate). Reports on generic versions are filed under their own applications.
Reports
19,732
Serious
14,449
73% of reports
Hospitalization
6,326
Death reported
4,290
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death3,250
- diarrhoea2,897
- needle issue2,397
- fatigue2,316
- malaise2,248
- blood pressure increased2,087
- pain1,838
- nausea1,820
- malignant neoplasm progression1,774
- blood pressure systolic increased1,697
- abdominal pain1,673
- asthenia1,647
- injection site pain1,574
- weight decreased1,536
- inappropriate schedule of product administration1,504
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 28 |
| 2005 | 28 |
| 2006 | 48 |
| 2007 | 48 |
| 2008 | 58 |
| 2009 | 112 |
| 2010 | 170 |
| 2011 | 178 |
| 2012 | 280 |
| 2013 | 293 |
| 2014 | 911 |
| 2015 | 1,784 |
| 2016 | 2,378 |
| 2017 | 2,220 |
| 2018 | 2,307 |
| 2019 | 1,648 |
| 2020 | 2,147 |
| 2021 | 1,931 |
| 2022 | 900 |
| 2023 | 930 |
| 2024 | 619 |
| 2025 | 441 |
| 2026 | 273 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,427 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood pressure systolic increasedSignal | 1,697 | 101.5 | 96.8 | 154,253 |
| needle issueSignal | 2,397 | 95.5 | 91.9 | 206,002 |
| malignant neoplasm progressionSignal | 1,774 | 18.8 | 17.9 | 29,458 |
| blood pressure increasedSignal | 2,087 | 14.7 | 14.1 | 26,540 |
| inappropriate schedule of product administrationSignal | 1,504 | 9.0 | 8.5 | 10,633 |
| abdominal painSignal | 1,673 | 7.7 | 7.4 | 9,808 |
| weight decreasedSignal | 1,536 | 5.9 | 5.6 | 6,283 |
| injection site painSignal | 1,574 | 5.5 | 5.2 | 5,835 |
| malaiseSignal | 2,248 | 5.5 | 5.3 | 8,375 |
| diarrhoeaSignal | 2,897 | 4.8 | 4.6 | 8,949 |
| astheniaSignal | 1,647 | 4.7 | 4.5 | 4,836 |
| deathSignal | 3,250 | 4.0 | 3.9 | 7,696 |
| painSignal | 1,838 | 3.2 | 3.1 | 2,846 |
| fatigueSignal | 2,316 | 3.2 | 3.1 | 3,576 |
| nauseaSignal | 1,820 | 2.5 | 2.3 | 1,625 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.